Request Demo
Last update 15 Nov 2025
Anti-CD30 CAR-T (Shanghai SongGe )
Last update 15 Nov 2025
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD30 inhibitors(Tumor necrosis factor receptor superfamily member 8 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
5
Clinical Trials associated with Anti-CD30 CAR-T (Shanghai SongGe )NCT06756321
An Exploratory Clinical Study of the Safety and Efficacy of Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Subjects with Relapsed/Refractory Hematologic Malignancy
ChiCTR2200056525
An exploratory clinical study to evaluate the safety and efficacy of anti CD30 CAR T cell injection (anti CD30 CAR T cells) in patients with CD30+relapsed/refractory lymphoma
NCT05208853
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells Injection (Anti CD30 CAR T Cells) in Patients With CD30+ Relapsed/Refractory Lymphoma
100 Clinical Results associated with Anti-CD30 CAR-T (Shanghai SongGe )
Login to view more data
100 Translational Medicine associated with Anti-CD30 CAR-T (Shanghai SongGe )
Login to view more data
100 Patents (Medical) associated with Anti-CD30 CAR-T (Shanghai SongGe )
Login to view more data
100 Deals associated with Anti-CD30 CAR-T (Shanghai SongGe )
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Recurrent Hematologic Malignancy | Phase 1 | China | 18 Sep 2023 | |
| Recurrent Lymphoma | Phase 1 | China | 18 Sep 2023 | |
| Refractory Hematologic Malignancy | Phase 1 | China | 18 Sep 2023 | |
| Refractory Lymphoma | Phase 1 | China | 18 Sep 2023 | |
| Anaplastic Large-Cell Lymphoma | Phase 1 | China | 10 Feb 2022 | |
| CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma | Phase 1 | China | 10 Feb 2022 | |
| Extranodal NK-T-Cell Lymphoma | Phase 1 | China | 10 Feb 2022 | |
| Gray Zone Lymphoma | Phase 1 | China | 10 Feb 2022 | |
| Hodgkin's Lymphoma | Phase 1 | China | 10 Feb 2022 | |
| Immunoblastic Lymphadenopathy | Phase 1 | China | 10 Feb 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free